

Carbamazepine Syrup 40 mg/mL

INGREDIENTS:

Carbamazepine 200 mg tablet	24 tablets
Simple syrup	QSAD: 120 mL

EQUIPMENT AND SUPPLIES:

Containment ventilated enclosure (CVE) or biological safety cabinet (BSC), mortar and pestle, graduated cylinder

PREPARATION DETAILS:

Caution: Hazardous Drug—Non-antineoplastic hazardous drug: Must be prepared in compliance with USP <800>.

1. Triturate tablets to a fine powder with a mortar and pestle.
2. Levigate powder with a small amount of vehicle to form a paste.
3. Add vehicle in increasing amounts while mixing thoroughly.
4. Transfer contents of the mortar to a graduated cylinder.
5. Rinse the mortar and pestle with vehicle and pour into graduated cylinder.
6. Add vehicle to the graduated cylinder to achieve the total volume indicated above.
7. Transfer contents of the graduated cylinder into an appropriately sized amber bottle.
8. Shake well to mix.

Quality-Control Procedures — Visually inspect for physical appearance of formulation and container closure integrity (no leakage, cracks in container, or improper seals).

Labeling Requirements — Extemporaneously compounded preparation. Caution: hazardous drug. For oral use only. Store at room temperature or refrigerate. Shake well before use.

Storage Conditions/Stability — Store bottle at room temperature or refrigerate. Refrigerate unit dose syringe. Stable for 90 days.

STABILITY STUDY DETAILS:

Study Container Type — Amber glass bottle and unit dose syringe

Referenced Manufacturer — Carbamazepine tablets (Ciba-Geigy Corp); simple syrup (not specified).

Stability-Indicating Study — Yes

Commercially available as a 20-mg/mL suspension — Use extemporaneously prepared formulation only when commercial product is unavailable or a more concentrated syrup is desired.

REFERENCE

1. Burckart CJ, Hammond RW, Akers MJ. Stability of extemporaneous suspensions of carbamazepine. *Am J Hosp Pharm.* 1981;38(12):1929-1931.